Skip to main content
Content Medically Reviewed & Updated: February 28, 2026 Call 24/7: 1-800-400-1805
1-800-400-1805 Free Case Review
Diagnosed? Get a Free Mesothelioma Case Review No cost · No obligation · Attorneys available 24/7 Get Started
Trusted Mesothelioma & Lung Cancer Resource Since 2003

Pleural Mesothelioma

Pleural mesothelioma is the most common type of mesothelioma, developing in the pleural lining that surrounds the lungs. Caused by inhaling microscopic asbestos fibers, this aggressive cancer typically appears 20 to 50 years after exposure. Early detection and a multimodal treatment approach can significantly improve outcomes and quality of life.

75–80% Of All Mesothelioma Cases
12–21 Mo. Median Survival
$1M–$3M+ Average Compensation
$0 Upfront Legal Cost

Diagnosed with Pleural Mesothelioma? Get a Free Case Review

Find out if you qualify for compensation. Free, confidential review.

Your information is confidential. No fees unless we win.

BBB A+ Accredited Since 2009
Super Lawyers Multiple Years Selected
National Trial Lawyers Top 100 Trial Lawyers
AV Preeminent Martindale-Hubbell Rated
AAJ Member American Association for Justice
$2B+ Recovered for Clients
Medically reviewed and updated: • Sources: NCI, ACS, NCCN, SEER

What Is Pleural Mesothelioma?

Pleural mesothelioma is a rare, aggressive cancer that develops in the pleura — the thin, two-layered membrane that lines the chest cavity and covers the surface of the lungs. It is the most common form of mesothelioma, accounting for approximately 75% to 80% of all diagnosed cases. The disease is caused almost exclusively by the inhalation of microscopic asbestos fibers, which become permanently embedded in the pleural tissue and trigger malignant cellular changes over decades.

The pleura consists of two layers: the visceral pleura, which covers the lungs directly, and the parietal pleura, which lines the inside of the chest wall. Between these layers is a thin space containing a small amount of fluid that allows the lungs to expand and contract smoothly during breathing. When asbestos fibers lodge in the pleural tissue, they cause chronic inflammation, scarring (fibrosis), and DNA damage that can eventually lead to the development of malignant pleural mesothelioma.

Unlike lung cancer, which develops within the lung tissue itself, pleural mesothelioma grows along the surface of the pleural lining and can spread to encase the lung, restrict its movement, and cause fluid to accumulate in the pleural space (a condition known as pleural effusion). As the disease progresses, tumors may spread to the chest wall, diaphragm, lymph nodes, and distant organs.

How Asbestos Causes Pleural Mesothelioma

When asbestos-containing materials are disturbed during manufacturing, construction, renovation, or demolition, they release microscopic fibers into the air. These fibers are so small that they can be inhaled deep into the lungs, where they travel to the outermost lung tissue and penetrate the pleural lining. Once embedded, the body cannot break down or expel these fibers. Over a latency period of 20 to 50 years, the trapped fibers cause:

  • Chronic pleural inflammation — the body's immune response to the foreign fibers creates persistent irritation
  • Pleural fibrosis and thickening — scar tissue develops around the trapped fibers, thickening the pleural membrane
  • DNA damage and genetic mutations — asbestos fibers physically interfere with cell division and generate reactive oxygen species that damage DNA
  • Malignant transformation — accumulated genetic damage eventually causes mesothelial cells to grow uncontrollably, forming tumors

No Safe Level of Asbestos Exposure

There is no known safe threshold for asbestos exposure. Even brief or low-level exposure — including secondary exposure from a family member's contaminated work clothing — has been documented to cause pleural mesothelioma. Workers in high-risk occupations such as shipyard workers, construction workers, industrial plant employees, and military veterans face the greatest risk, but anyone with any history of asbestos exposure may be at risk.

~3,000 U.S. Cases Diagnosed Per Year
75–80% Are Pleural Mesothelioma
20–50 Yrs Latency Period After Exposure
1 in 3 Patients Are Veterans

Symptoms & Early Warning Signs

Pleural mesothelioma symptoms develop gradually and are often mistaken for more common respiratory conditions such as pneumonia, bronchitis, or COPD. This is one reason why the disease is frequently diagnosed at an advanced stage. Recognizing the early warning signs — particularly in anyone with a history of asbestos exposure — is critical for earlier detection and better treatment outcomes.

Common Symptoms of Pleural Mesothelioma

  • Persistent dry cough — a chronic cough that does not respond to standard treatments and worsens over time
  • Chest pain or tightness — pain in the chest wall or lower back caused by tumor growth along the pleural lining
  • Shortness of breath (dyspnea) — difficulty breathing caused by pleural effusion or tumor encasement of the lung
  • Pleural effusion — abnormal buildup of fluid between the two pleural layers, compressing the lung and reducing its capacity
  • Unexplained weight loss — significant, unintentional weight loss often occurring in the months before diagnosis
  • Fatigue — persistent exhaustion and reduced energy that does not improve with rest
  • Night sweats and low-grade fever — systemic symptoms that may accompany the body's inflammatory response to the cancer
  • Difficulty swallowing (dysphagia) — can occur when tumors press on the esophagus in advanced disease

Tell Your Doctor About Your Asbestos History

If you have any history of asbestos exposure and are experiencing respiratory symptoms — even mild ones — it is essential to inform your doctor. Pleural mesothelioma is frequently misdiagnosed as other lung conditions because the symptoms overlap significantly. Disclosing your asbestos exposure history can prompt your physician to order the specific imaging and tests needed for an accurate and timely diagnosis. Learn more about diagnosis and treatment options.

Symptoms by Stage

Stage Typical Symptoms Notes
Stage I–II (Early) Mild shortness of breath, slight chest discomfort, occasional dry cough Symptoms often subtle or absent; frequently discovered incidentally on imaging
Stage III (Locally Advanced) Worsening dyspnea, persistent chest pain, pleural effusion, fatigue, weight loss Most patients are diagnosed at this stage; surgery may still be an option
Stage IV (Advanced/Metastatic) Severe breathing difficulty, significant pain, difficulty swallowing, body aches, extreme fatigue Cancer has spread beyond the chest; treatment focuses on symptom management and quality of life
Medically reviewed and updated: • Sources: NCI, NCCN, ACS

How Pleural Mesothelioma Is Diagnosed

Diagnosing pleural mesothelioma requires a multi-step approach involving imaging studies, blood biomarker tests, and ultimately a tissue biopsy for definitive confirmation. Because the disease mimics other lung conditions, an accurate diagnosis often requires specialized evaluation by a thoracic oncologist or a mesothelioma specialist.

Imaging Studies

The diagnostic process typically begins with imaging to visualize abnormalities in the chest:

  • Chest X-ray — often the first imaging study ordered; may reveal pleural effusion, pleural thickening, or masses along the chest wall
  • CT scan (computed tomography) — provides detailed cross-sectional images of the chest, showing the location, size, and extent of pleural tumors, effusion, and any involvement of nearby structures
  • PET scan (positron emission tomography) — uses a radioactive tracer to identify metabolically active cancer cells, helping determine if the disease has spread beyond the pleura to lymph nodes or distant organs
  • MRI (magnetic resonance imaging) — provides superior soft-tissue detail; particularly useful for evaluating diaphragm and chest wall involvement before surgical planning

Blood Biomarkers

While no blood test can definitively diagnose pleural mesothelioma, certain biomarkers can support the diagnosis and help monitor treatment response:

  • Soluble mesothelin-related peptides (SMRP) — elevated in approximately 84% of pleural mesothelioma patients; the most established blood biomarker for this disease
  • Fibulin-3 — a newer biomarker that has shown promise in distinguishing mesothelioma from benign pleural conditions and may help detect the disease at earlier stages
  • Osteopontin — elevated levels have been associated with mesothelioma, though it is less specific than SMRP

Tissue Biopsy (Definitive Diagnosis)

A tissue biopsy is required to confirm the diagnosis of pleural mesothelioma. The biopsy determines the cell type (histology), which directly influences treatment decisions and prognosis:

  • Thoracoscopy (VATS — video-assisted thoracoscopic surgery) — the preferred biopsy method; a small camera is inserted through a small incision in the chest wall, allowing the surgeon to directly visualize the pleura and obtain multiple tissue samples
  • CT-guided core needle biopsy — a needle is inserted through the chest wall under CT guidance to extract tissue from a pleural mass; less invasive but may yield smaller tissue samples
  • Thoracentesis with cytology — fluid is drained from the pleural space and examined for cancer cells; while useful for symptom relief, fluid cytology alone is insufficient for a definitive mesothelioma diagnosis in many cases

Staging

After a confirmed diagnosis, staging determines how far the cancer has spread and guides treatment planning. Pleural mesothelioma uses the TNM staging system (Tumor, Nodes, Metastasis):

Stage Description Treatment Options
Stage I Cancer is confined to the pleural lining on one side of the chest Surgery (EPP or P/D) + chemotherapy + radiation (multimodal)
Stage II Cancer has spread within the pleura and may involve the diaphragm or lung tissue on one side Surgery + chemotherapy + radiation; clinical trials
Stage III Cancer has spread to nearby lymph nodes, chest wall, pericardium, or mediastinal tissues Chemotherapy, immunotherapy, radiation; surgery possible in select cases
Stage IV Cancer has spread to distant organs (liver, bones, brain, opposite chest) Immunotherapy, chemotherapy, palliative care, clinical trials

Treatment Options for Pleural Mesothelioma

Treatment for pleural mesothelioma depends on the stage of the disease, the cell type, the patient's overall health, and their treatment goals. The most effective approach for eligible patients is multimodal therapy — a combination of surgery, chemotherapy, immunotherapy, and/or radiation therapy. Recent advances, including FDA-approved immunotherapy, have expanded treatment options and improved outcomes for many patients.

Surgery

Surgery offers the best chance for long-term survival when the cancer is detected at an early stage (Stage I or II) and the patient is in good overall health. Two primary surgical procedures are used for pleural mesothelioma:

  • Extrapleural pneumonectomy (EPP) — removal of the affected lung, the pleura, the diaphragm, and the pericardium (heart lining) on the affected side. EPP is the more aggressive option and is intended to remove as much visible tumor as possible. It carries higher surgical risk but may provide the most complete tumor resection.
  • Pleurectomy/decortication (P/D) — removal of the pleural lining and all visible tumor tissue while preserving the lung. P/D is less invasive than EPP, carries lower surgical mortality, and allows patients to retain lung function. It has become the preferred surgical approach at many major mesothelioma treatment centers.

Chemotherapy

Chemotherapy is the standard systemic treatment for pleural mesothelioma and is used in most treatment plans, either before surgery (neoadjuvant), after surgery (adjuvant), or as a primary treatment for patients who are not surgical candidates:

  • Pemetrexed (Alimta) + cisplatin — the standard first-line chemotherapy regimen for malignant pleural mesothelioma. This combination was FDA-approved in 2004 and improves median survival by several months compared to cisplatin alone.
  • Pemetrexed + carboplatin — an alternative combination for patients who cannot tolerate cisplatin; generally produces similar efficacy with a more manageable side effect profile.

Immunotherapy

Immunotherapy has become a significant treatment advancement for pleural mesothelioma, offering a new first-line option for patients with unresectable disease:

CheckMate 743: FDA-Approved Immunotherapy for Pleural Mesothelioma

In October 2020, the FDA approved the combination of nivolumab (Opdivo) + ipilimumab (Yervoy) as a first-line treatment for unresectable malignant pleural mesothelioma, based on the landmark CheckMate 743 clinical trial. This study demonstrated that immunotherapy improved overall survival compared to standard chemotherapy, with a median overall survival of 18.1 months versus 14.1 months for chemotherapy. The benefit was particularly striking for patients with non-epithelioid (sarcomatoid or biphasic) cell types, who historically had the poorest prognosis with chemotherapy alone.

Radiation Therapy

Radiation is typically used as part of a multimodal treatment plan rather than as a standalone therapy for pleural mesothelioma:

  • Adjuvant radiation — delivered after surgery (EPP or P/D) to destroy remaining microscopic cancer cells and reduce the risk of recurrence
  • Intensity-modulated radiation therapy (IMRT) — advanced technique that precisely shapes radiation beams to target tumor areas while minimizing damage to surrounding healthy tissue
  • Palliative radiation — used to relieve pain, reduce tumor size, and improve quality of life in patients with advanced disease

The Multimodal Approach

The most effective treatment strategy for eligible patients combines two or more treatment modalities. A common multimodal approach is surgery (P/D) followed by chemotherapy (pemetrexed + cisplatin) and adjuvant radiation therapy. Studies have shown that patients who receive multimodal treatment have significantly longer survival times than those who receive any single therapy alone. Treatment decisions should be made by a multidisciplinary team with experience in mesothelioma at a specialized cancer center.

18.1 Mo. Median Survival with Immunotherapy (CheckMate 743)
P/D Lung-Sparing Surgery Now Preferred
2004 Pemetrexed+Cisplatin FDA Approved
2020 Nivo+Ipi FDA Approved
Medically reviewed and updated: • Sources: NCI SEER, NCCN, CheckMate 743

Prognosis & Survival Rates

The prognosis for pleural mesothelioma depends on several factors, including the stage at diagnosis, cell type (histology), the patient's age and overall health, and the treatment approach. While pleural mesothelioma remains a serious diagnosis, advances in treatment — particularly immunotherapy and multimodal surgical approaches — are improving outcomes for many patients.

Survival by Stage

Stage Median Survival 5-Year Survival Rate
Stage I 21+ months ~20%
Stage II 19 months ~12%
Stage III 16 months ~8%
Stage IV 12 months or less ~5%

Survival by Cell Type (Histology)

The cell type of pleural mesothelioma is one of the most important prognostic factors. There are three primary histological types:

Cell Type Frequency Median Survival Treatment Response
Epithelioid ~60–70% 14–19 months Best response to surgery and chemotherapy; most favorable prognosis
Biphasic (Mixed) ~20–30% 10–15 months Prognosis depends on the ratio of epithelioid to sarcomatoid cells; responds to immunotherapy
Sarcomatoid ~10–15% 4–12 months Most aggressive; poorest prognosis with chemotherapy but shows significant benefit from immunotherapy (CheckMate 743)

Factors That Improve Prognosis

  • Early-stage diagnosis (Stage I or II) — allows for curative-intent surgery as part of multimodal treatment
  • Epithelioid cell type — responds best to standard treatments and carries the longest survival
  • Younger age and good performance status — patients who are physically fit enough to undergo surgery and tolerate aggressive treatment tend to have better outcomes
  • Multimodal treatment — patients who receive a combination of surgery, chemotherapy, and/or radiation consistently outlive those who receive single-modality treatment
  • Treatment at a specialized mesothelioma center — outcomes improve when care is delivered by a multidisciplinary team experienced in treating mesothelioma
  • Immunotherapy for non-epithelioid — the CheckMate 743 immunotherapy regimen has significantly improved survival for sarcomatoid and biphasic patients, who previously had the poorest prognosis

Emerging Treatments Are Extending Survival

Clinical research continues to advance. Gene therapy, tumor treating fields (TTFields), CAR-T cell therapy, and combination immunotherapy regimens are being studied in active clinical trials. Patients diagnosed today have access to more treatment options — and a more hopeful outlook — than at any previous point in the history of this disease. Speak with a mesothelioma specialist about clinical trial eligibility.

Legal Rights & Compensation

If you or a loved one has been diagnosed with pleural mesothelioma, you have legal rights to seek compensation from the companies responsible for your asbestos exposure. Asbestos manufacturers knew their products were dangerous for decades but chose to conceal the risks from workers and the public. Mesothelioma patients and their families have recovered billions of dollars through trust fund claims, personal injury lawsuits, and other legal actions.

Sources of Compensation

  • Asbestos trust funds — over $30 billion remains available across 60+ active trust funds established by bankrupt asbestos manufacturers. Claims are filed directly with the trust and do not require going to trial. Most trust fund claims are resolved within 6 to 12 months.
  • Personal injury lawsuits — mesothelioma patients can file lawsuits against the companies that manufactured, distributed, or used asbestos-containing products. Settlements typically range from $1 million to $1.4 million, and trial verdicts have exceeded $10 million in many cases.
  • Wrongful death claims — surviving family members may file wrongful death claims after a mesothelioma patient passes away. These claims seek compensation for medical expenses, lost income, funeral costs, and the family's emotional loss.
  • VA benefits for veterans — veterans diagnosed with mesothelioma due to military asbestos exposure are eligible for VA disability benefits, typically rated at 100% disability. VA benefits include monthly compensation, healthcare, Aid and Attendance, and Dependency and Indemnity Compensation (DIC) for surviving spouses. Visit our veterans page for more information.
  • Workers' compensation — in some states, workers diagnosed with asbestos-related diseases may also file workers' compensation claims, though time limits and eligibility vary by state.

Statute of Limitations

Every state has a statute of limitations that sets a deadline for filing mesothelioma claims. In most states, the statute of limitations begins at the time of diagnosis, not the time of asbestos exposure. Because pleural mesothelioma has a latency period of 20 to 50 years, patients are typically diagnosed long after their exposure occurred. It is critical to consult with a mesothelioma attorney as soon as possible after diagnosis to ensure your legal rights are preserved.

No Upfront Legal Fees

Mesothelioma attorneys work on a contingency fee basis, meaning you pay nothing unless compensation is recovered for you. The initial consultation is free and confidential. Our attorneys at Danziger & De Llano have been representing mesothelioma patients and families for over 35 years and have recovered over $2 billion in compensation for asbestos-exposed clients nationwide.

$30B+ Available in Asbestos Trust Funds
$1M–$1.4M Average Settlement
100% VA Disability Rating for Meso
$0 Upfront Legal Cost

Diagnosed with Pleural Mesothelioma? Get a Free Case Review

Our experienced mesothelioma attorneys have helped thousands of patients and families recover the compensation they deserve after an asbestos-related diagnosis. We will review your exposure history, identify every responsible manufacturer, and pursue all available trust funds and legal claims. There is no cost, no pressure, and no obligation.

$2B+ Recovered Our firm has recovered over $2 billion for mesothelioma and asbestos patients and their families.
No Upfront Fees You pay nothing unless we recover compensation for you. Free and confidential consultation.
35+ Years Experience Danziger & De Llano has been representing mesothelioma patients and families for over three decades.
Nationwide Service Licensed to handle mesothelioma cases in all 50 states from our Houston office.

Or call us 24/7: 1-800-400-1805

Take the First Step — It's Free

By submitting this form, you agree to be contacted about your potential case. Your information is confidential and protected. No fees unless we recover compensation for you. This is attorney advertising. Past results do not guarantee future outcomes.

FAQ answers reviewed by legal team:

Frequently Asked Questions About Pleural Mesothelioma

What is pleural mesothelioma?

Pleural mesothelioma is a rare and aggressive cancer that develops in the pleura, the thin membrane that lines the lungs and chest cavity. It is the most common type of mesothelioma, accounting for approximately 75% to 80% of all diagnosed cases. The disease is caused almost exclusively by inhaling asbestos fibers, which become embedded in the pleural tissue and cause malignant changes over a latency period of 20 to 50 years. Approximately 3,000 people are diagnosed with mesothelioma in the United States each year, with the majority being the pleural type.

What are the early symptoms of pleural mesothelioma?

Early symptoms of pleural mesothelioma include persistent dry cough, shortness of breath, chest pain or tightness, pleural effusion (fluid buildup between the lung and chest wall), unexplained weight loss, and fatigue. These symptoms are often subtle and are frequently misdiagnosed as pneumonia, COPD, or other common respiratory conditions. Anyone with a history of asbestos exposure who develops these symptoms should inform their doctor about their exposure history so that the appropriate diagnostic tests can be ordered promptly.

What is the survival rate for pleural mesothelioma?

The median survival for pleural mesothelioma is 12 to 21 months after diagnosis, though outcomes vary significantly based on stage at diagnosis, cell type, and treatment received. Patients with epithelioid cell type have the most favorable prognosis with a median survival of 14 to 19 months. Patients diagnosed at Stage I or II who receive multimodal treatment — combining surgery, chemotherapy, and radiation — have achieved 5-year survival rates of 20% or higher. The FDA-approved immunotherapy combination of nivolumab + ipilimumab (CheckMate 743) has improved survival for patients with non-epithelioid cell types.

Can pleural mesothelioma patients receive compensation?

Yes. Pleural mesothelioma patients and their families may be eligible for significant compensation through multiple sources: asbestos trust fund claims (over $30 billion remains available across 60+ trusts), personal injury lawsuits against asbestos product manufacturers, wrongful death claims for surviving family members, and VA disability benefits for veterans (typically rated at 100% for mesothelioma). The average mesothelioma settlement ranges from $1 million to $1.4 million, and trial verdicts have exceeded $10 million. Mesothelioma attorneys work on a contingency fee basis — you pay nothing unless compensation is recovered for you.

This page was last reviewed and updated on by the legal and medical team at Danziger & De Llano, LLP.

Sources & References

  1. National Cancer Institute — Mesothelioma Treatment (PDQ)
  2. American Cancer Society — Malignant Mesothelioma
  3. NCI SEER Program — Mesothelioma Cancer Stat Facts
  4. NCCN — Mesothelioma Patient Guidelines
  5. FDA — Approval of Nivolumab + Ipilimumab for Pleural Mesothelioma
  6. New England Journal of Medicine — CheckMate 743: Nivolumab Plus Ipilimumab in Unresectable Mesothelioma (Baas et al., 2021)
  7. National Library of Medicine — Updates in Malignant Pleural Mesothelioma (2018)
  8. American Thoracic Society — Mesothelioma Patient Information

Have You or a Loved One Been Diagnosed with Pleural Mesothelioma?

Pleural mesothelioma is caused by asbestos exposure, and the companies responsible can be held accountable. If you or a family member has been diagnosed, you may be entitled to significant compensation from asbestos trust funds, lawsuits, and VA benefits. Our attorneys have spent over 35 years helping mesothelioma patients and families get the justice they deserve.

Call 1-800-400-1805 Request a Free Case Review

Free consultation • No obligation • Available 24/7 • No fees unless we win

BBB A+ Accredited 4.8★ Google Rating $2B+ Recovered 35+ Years Experience
Call Now: (800) 400-1805 Free Case Review • Available 24/7